Cargando…
Disease understanding in patients newly diagnosed with atrial fibrillation
OBJECTIVE: To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861387/ https://www.ncbi.nlm.nih.gov/pubmed/28790169 http://dx.doi.org/10.1136/heartjnl-2017-311800 |
_version_ | 1783308082398363648 |
---|---|
author | Kaufman, Brystana G Kim, Sunghee Pieper, Karen Allen, Larry A Gersh, Bernard J Naccarelli, Gerald V Ezekowitz, Michael D Fonarow, Gregg C Mahaffey, Kenneth W Singer, Daniel E Chan, Paul S Freeman, James V Ansell, Jack Kowey, Peter R Rieffel, James A Piccini, Jonathan Peterson, Eric O’Brien, Emily C |
author_facet | Kaufman, Brystana G Kim, Sunghee Pieper, Karen Allen, Larry A Gersh, Bernard J Naccarelli, Gerald V Ezekowitz, Michael D Fonarow, Gregg C Mahaffey, Kenneth W Singer, Daniel E Chan, Paul S Freeman, James V Ansell, Jack Kowey, Peter R Rieffel, James A Piccini, Jonathan Peterson, Eric O’Brien, Emily C |
author_sort | Kaufman, Brystana G |
collection | PubMed |
description | OBJECTIVE: To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. METHODS: We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. RESULTS: Among 1004 baseline survey responses, patients’ confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with ‘high’ understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting ‘high’ disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. CONCLUSIONS: About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov. Identifier: NCT01701817. |
format | Online Article Text |
id | pubmed-5861387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58613872018-03-22 Disease understanding in patients newly diagnosed with atrial fibrillation Kaufman, Brystana G Kim, Sunghee Pieper, Karen Allen, Larry A Gersh, Bernard J Naccarelli, Gerald V Ezekowitz, Michael D Fonarow, Gregg C Mahaffey, Kenneth W Singer, Daniel E Chan, Paul S Freeman, James V Ansell, Jack Kowey, Peter R Rieffel, James A Piccini, Jonathan Peterson, Eric O’Brien, Emily C Heart Arrhythmias and Sudden Death OBJECTIVE: To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. METHODS: We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. RESULTS: Among 1004 baseline survey responses, patients’ confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with ‘high’ understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting ‘high’ disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. CONCLUSIONS: About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov. Identifier: NCT01701817. BMJ Publishing Group 2018-03 2017-08-08 /pmc/articles/PMC5861387/ /pubmed/28790169 http://dx.doi.org/10.1136/heartjnl-2017-311800 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Arrhythmias and Sudden Death Kaufman, Brystana G Kim, Sunghee Pieper, Karen Allen, Larry A Gersh, Bernard J Naccarelli, Gerald V Ezekowitz, Michael D Fonarow, Gregg C Mahaffey, Kenneth W Singer, Daniel E Chan, Paul S Freeman, James V Ansell, Jack Kowey, Peter R Rieffel, James A Piccini, Jonathan Peterson, Eric O’Brien, Emily C Disease understanding in patients newly diagnosed with atrial fibrillation |
title | Disease understanding in patients newly diagnosed with atrial fibrillation |
title_full | Disease understanding in patients newly diagnosed with atrial fibrillation |
title_fullStr | Disease understanding in patients newly diagnosed with atrial fibrillation |
title_full_unstemmed | Disease understanding in patients newly diagnosed with atrial fibrillation |
title_short | Disease understanding in patients newly diagnosed with atrial fibrillation |
title_sort | disease understanding in patients newly diagnosed with atrial fibrillation |
topic | Arrhythmias and Sudden Death |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861387/ https://www.ncbi.nlm.nih.gov/pubmed/28790169 http://dx.doi.org/10.1136/heartjnl-2017-311800 |
work_keys_str_mv | AT kaufmanbrystanag diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT kimsunghee diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT pieperkaren diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT allenlarrya diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT gershbernardj diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT naccarelligeraldv diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT ezekowitzmichaeld diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT fonarowgreggc diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT mahaffeykennethw diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT singerdaniele diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT chanpauls diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT freemanjamesv diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT anselljack diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT koweypeterr diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT rieffeljamesa diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT piccinijonathan diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT petersoneric diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation AT obrienemilyc diseaseunderstandinginpatientsnewlydiagnosedwithatrialfibrillation |